Diadem srl, kambani inogadzira bvunzo dzeropa-yekufanotaura kwekutanga uye kuongororwa kwechirwere cheAlzheimer (AD), nhasi yazivisa kuti yakapa data paAD/PD™ 2022 International Musangano pamusoro peAlzheimer's and Parkinson's Diseases (AD/PD22) inoratidza izvozvo. yayo itsva AlzoSure® Confirm bvunzo ropa anogona kunyatsoona varwere chirwere cheAlzheimer. Mharidzo iyi, "Yekutanga Isingapindire Ropa-Yakavakirwa Muedzo weKuongororwa kweChirwere cheAlzheimer uye Zvimwe Dementias," yakapihwa naDiadem mukuru mukuru Paul Kinnon pamusangano muBarcelona, Spain munaKurume 19, 2022.
AlzoSure® Confirm yakagadziridzwa papuratifomu yetekinoroji iyo iri pasi peAlzoSure® Predict, Diadem's prognostic blood test iyo inogona kufanotaura nemazvo kana munhu ane kukurumidza kushanduka kwekuziva achaenderera kuchirwere cheAlzheimer kusvika makore matanhatu mamiriro acho asati anyatsoratidzwa. AlzoSure® Predict yakasarudzwa seBreakthrough Chishandiso neUS Food & Drug Administration uye nguva pfupi yadarika yakawana mucherechedzo weEC-IVD uchiibvumidza kutengeswa kuUK neEuropean Union.
Chiyero chitsva chakavakirwa pane imwecheteyo U-p53AZ inosanganisa biomarker-yakasiyana-siyana yep53-iyo yakave yakabatana neiyo pathogenesis yeAD muzvidzidzo zvinopfuura mazana mana, nekudyidzana kwakanyorwa neamyloid, tau nezvimwe zvinhu zvine chekuita nekufambira mberi kwevarwere. kusvika AD. Diadem's patented tekinoroji yakagadziridzwa ichishandisa yayo U-p400AZ chikuva.
Muchidzidzo chakaitwa paAD/PD22, vatsvakurudzi veDiadem vakashandisa chikamu chemasampuli kubva mudura renguva refu revarwere vangangosvika mazana mashanu vachiratidza matanho akasiyana ekuderera kwekuziva kuti vaferefete kutevedzana kuzere kwekushandurwa kwemashure eshanduro (PTMs) yeU-p500AZ panguva iyi. yekuenderera mberi kunoguma nechirwere cheAlzheimer. Vakaona kuti chaiyo PTM “mafingerprints,” kana masiginicha, aive hunhu hwematanho akasiyana ekufambira mberi kuenda kuAD. AlzoSure® Confirm inoshandisa siginecha yePTM inoratidza chirwere cheAlzheimer's chakazara kuti ipe ongororo yeropa-based biomarker inogona kukwanisa kuongorora AD. Mukutanga kiriniki yekusimbisa data Diadem yakaratidzwa kuAD/PD53, iyi siginecha yePTM yakakwanisa kuona nekuvimbika varwere vane AD uye kuvasiyanisa kubva kune varwere vane humwe dementia.
"KuDiadem, takazvipira kuvandudza kuongororwa kweropa uye kuongororwa kweropa kunokwanisa kunyatsoona vanhu vane chirwere cheAlzheimer kana kuti vachaenda kuAD mumakore anotevera," akadaro Mr. Kinnon. "Yedu yeAlzoSure® Predict prognostic test yeropa yakatove yakasimbiswa muzvidzidzo zvekiriniki yakakura uye ichave iripo muEU gare gare gore rino. Isu tinofara zvikuru nezve bvunzo yedu itsva yeAlzoSure® Confirm, ine mukana wekunyatsoongorora uye kunyatsoongorora chirwere cheAlzheimer uchishandisa ongororo yeropa iri nyore. Kushaikwa kwekuongorora kunoenderana nenguva, kwakaringana uye kusingadhuri kwakatadzisa kufambira mberi mukugadzira nzira dzekurapa dzinoshanda dzevarwere veAD, uye isu tinotarisira kushanda pamwe nevakasiyana siyana kugadzira uye kuzivisa data rinosimbisa paAlzoSure® Confirm.
ZVOKUBVA MUNYAYA INO:
- In the study presented at AD/PD22, Diadem researchers used a subset of samples from a longitudinal database of almost 500 patients exhibiting different stages of cognitive decline to investigate the full sequence of post-translational modifications (PTMs) of U-p53AZ over the course of the continuum that culminates in Alzheimer’s disease.
- Diadem srl, a company developing blood-based tests for the early prediction and diagnosis of Alzheimer’s disease (AD), today announced that it presented data at the AD/PD™ 2022 International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD22) showing that its new AlzoSure® Confirm blood test can accurately identify patients with Alzheimer’s disease.
- AlzoSure® Confirm has been developed on the same technology platform that underlies AlzoSure® Predict, Diadem’s prognostic blood test that can accurately predict whether or not an individual with early cognitive changes will progress to Alzheimer’s disease up to six years before the condition is fully manifested.
